R&D productivity has been declining for decades, but a record 53 new therapeutic drugs approved by the U.S. FDA in 2014 suggest that the biopharma industry's fortunes have changed.
Education
- PhD, Swiss Federal Institute of Technology (ETH), Zurich
- LLB, honors, Australian National University
- BSc , honors, , Australian National University
Honors and Awards
- University Medal, Australian National University
David is the leader of Boston Consulting Group's Health Care practice in Switzerland and has worked extensively with clients in the pharmaceutical and biotech industries in Europe, the US, and emerging markets.
David collaborates with clients on a broad range of strategic and operational topics including commercial, market access, medical affairs, R&D, corporate strategy, and large-scale transformations.
Prior to joining our Zurich office, David conducted doctoral research in molecular biotechnology, focusing on gene control and delivery applications for recombinant protein production and therapeutic use.
